VERONA PHARMA

VRNA

N/A

NASDAQHealthcare🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 29, 2026

18w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Ensifentrine 3 mg twice daily	Phase 3	COPD	-
Ensifentrine	Phase 3	Chronic Obstructive Pulmonary Disease	-
RPL554 suspension	Phase 2	COPD	-
Nebulized Ensifentrine Suspension; 3 mg	Phase 2	Non-cystic Fibrosis Bronchiectasis	-
Part A: RPL554	Phase 2	Pulmonary Disease, Chronic Obstructive	-
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium	Phase 2	COPD	-
Glycopyrrolate (85 μg)	Phase 2	Chronic Obstructive Pulmonary Disease	-
Tiotropium/olodaterol (Respimat)	Phase 2	COPD	-
Placebos	Phase 2	COPD	-
Ensifentrine 3 mg	Phase 2	Chronic Obstructive Pulmonary Disease	-
RPL554	Phase 2	Cystic Fibrosis	-
Salbutamol	Phase 2	Chronic Obstructive Pulmonary Disease	-
Glycopyrrolate 21.25 mcg	Phase 2	Chronic Obstructive Pulmonary Disease	-
Ensifentrine Dose 1	Phase 2	Coronavirus Infection	-
1.5 mg RPL554 plus tiotropium	Phase 2	Chronic Obstructive Pulmonary Disease Moderate	-
Placebo	Phase 2	Asthma	-

Catalyst Timeline

5 upcoming, 0 past

Phase 2Next

Ensifentrine 3 mg Phase 2 Results Expected

Apr 29, 2026Ensifentrine 3 mg

Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmonary Disease

Source

Phase 2

Glycopyrrolate 21.25 mcg Phase 2 Results Expected

Apr 29, 2026Glycopyrrolate 21.25 mcg

Primary completion for Glycopyrrolate 21.25 mcg trial (NCT07016412) in Chronic Obstructive Pulmonary Disease

Source

Phase 2

Nebulized Ensifentrine Suspension; 3 mg Phase 2 Results Expected

September 2026~Nebulized Ensifentrine Suspension; 3 mg

Primary completion for Nebulized Ensifentrine Suspension; 3 mg trial (NCT06559150) in Non-cystic Fibrosis Bronchiectasis

Source

Phase 2

Ensifentrine Phase 2 Results Expected

December 2026~Ensifentrine

Primary completion for Ensifentrine trial (NCT05270525) in COPD

Source

Phase 2

Placebo Phase 2 Results Expected

December 2026~Placebo

Primary completion for Placebo trial (NCT05270525) in COPD

Source

Regulatory Approvals

VRNA News

VERONA PHARMA

VRNA

N/A

NASDAQHealthcare🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 29, 2026

18w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Ensifentrine 3 mg twice daily	Phase 3	COPD	-
Ensifentrine	Phase 3	Chronic Obstructive Pulmonary Disease	-
RPL554 suspension	Phase 2	COPD	-
Nebulized Ensifentrine Suspension; 3 mg	Phase 2	Non-cystic Fibrosis Bronchiectasis	-
Part A: RPL554	Phase 2	Pulmonary Disease, Chronic Obstructive	-
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium	Phase 2	COPD	-
Glycopyrrolate (85 μg)	Phase 2	Chronic Obstructive Pulmonary Disease	-
Tiotropium/olodaterol (Respimat)	Phase 2	COPD	-
Placebos	Phase 2	COPD	-
Ensifentrine 3 mg	Phase 2	Chronic Obstructive Pulmonary Disease	-
RPL554	Phase 2	Cystic Fibrosis	-
Salbutamol	Phase 2	Chronic Obstructive Pulmonary Disease	-
Glycopyrrolate 21.25 mcg	Phase 2	Chronic Obstructive Pulmonary Disease	-
Ensifentrine Dose 1	Phase 2	Coronavirus Infection	-
1.5 mg RPL554 plus tiotropium	Phase 2	Chronic Obstructive Pulmonary Disease Moderate	-
Placebo	Phase 2	Asthma	-